Basic Information
| LncRNA/CircRNA Name | PCAT1 |
| Synonyms | LPCAT1, AGPAT10, AGPAT9, AYTL2, LPCAT-1, PFAAP3, lpcat, lysoPAFAT, PCAT-1 |
| Region | GRCh38_8:126556323-127419050 |
| Ensemble | ENSG00000253438 |
| Refseq | NR_045262 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Paclitaxel | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | oesophageal squamous cell carcinoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown |
| Sample | PCAT1, KYSE150 and KYSE450 cells, ESCC samples and adjacent normal tissues |
| Expression Pattern | up-regulated |
| Function Description | PCAT1 was highly expressed in ESCC tissues and cell lines. Knockdown of PCAT1 inhibited the growth of ESCC cells, whereas overexpression of PCAT1 showed the opposite effect both in vitro and in vivo. Moreover, knockdown of PCAT1 arrested the cell cycle at G2/M phase, reduced the expression of cyclin B1 and CDC2, and caused cells to be more sensitive to paclitaxel. Furthermore, PCAT1 could bind to miR-326, a tumour suppressor in diverse human cancers. Rescue experiments revealed that enforced expression of miR-326 attenuated the promotive effect of PCAT1 on ESCC cell growth. In addition, we discovered that PCAT1 was present in ESCC cell-derived exosomes, was higher in the serum of ESCC patients than those of healthy volunteer donors, and promoted cell growth through exosomes |
| Pubmed ID | 31273188 |
| Year | 2019 |
| Title | Long noncoding RNA PCAT1, a novel serum-based biomarker, enhances cell growth by sponging miR-326 in oesophageal squamous cell carcinoma |
External Links
| Links for PCAT1 | GenBank HGNC NONCODE |
| Links for oesophageal squamous cell carcinoma | OMIM COSMIC |